The firm has grown to become a fully-integrated specialty pharmaceutical company with the capability to develop, manufacture and commercialize a broad portfolio of Food and Drug Administration-approved drugs.

In January 2018 a major milestone was achieved by the privately-held drugmaker, with the  regulator approving Firvanq (vancomycin hydrochloride) oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.